翻訳と辞書 |
Lenvatinib
Lenvatinib (E7080; trade name Lenvima) is a multi-kinase inhibitor developed by Eisai Co. It inhibits both VEGFR2 and VEGFR3 kinases. Lenvatinib was granted orphan drug status for the treatment of various types of thyroid cancer that do not respond to radioiodine in the US and Japan in 2012 and in Europe in 2013. In February 2015, the FDA granted approval to lenvatinib (Lenvima) for treatment of progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).〔U.S. Food and Drug Administration. ''Hematology/Oncology (Cancer) Approvals & Safety Notifications.'' ()〕 ==Clinical trials== A phase I clinical trial was performed in 2006. A phase III trial started in March 2011.
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Lenvatinib」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|